Emerging therapeutic targets for cerebral edema
Ruchira M Jha1,2,3, Sudhanshu P Raikwar2, Sandra Mihaljevic2
1Department of Neurology, Barrow Neurological Institute and St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA.
Introduction:
Cerebral edema is a key contributor to death and disability in several forms of brain injury. Current treatment options are limited, reactive, and associated with significant morbidity. Targeted therapies are emerging based on a growing understanding of the molecular underpinnings of cerebral edema.
Areas Covered:
We review the pathophysiology and relationships between different cerebral edema subtypes to provide a foundation for emerging therapies. Mechanisms for promising molecular targets are discussed, with an emphasis on those advancing in clinical trials, including ion and water channels (AQP4, SUR1-TRPM4) and other proteins/lipids involved in edema signaling pathways (AVP, COX2, VEGF, and S1P). Research on novel treatment modalities for cerebral edema [including recombinant proteins and gene therapies] is presented and finally, insights on reducing secondary injury and improving clinical outcome are offered.
Expert Opinion:
Targeted molecular strategies to minimize or prevent cerebral edema are promising. Inhibition of SUR1-TRPM4 (glyburide/glibenclamide) and VEGF (bevacizumab) are currently closest to translation based on advances in clinical trials. However, the latter, tested in glioblastoma multiforme, has not demonstrated survival benefit. Research on recombinant proteins and gene therapies for cerebral edema is in its infancy, but early results are encouraging. These newer modalities may facilitate our understanding of the pathobiology underlying cerebral edema.
Insights
Targeted therapies for cerebral edema show promise by addressing molecular mechanisms. Emerging treatments like SUR1-TRPM4 inhibition and gene therapies offer new hope for reducing brain swelling and improving patient outcomes.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- Cerebral edema significantly contributes to death and disability following brain injury.
- Current treatments for cerebral edema are limited, reactive, and linked to substantial morbidity.
- Understanding the molecular basis of cerebral edema is crucial for developing targeted therapies.
Purpose of the Study:
- To review the pathophysiology and subtypes of cerebral edema.
- To discuss emerging molecular targets and novel treatment modalities for cerebral edema.
- To provide insights into reducing secondary injury and improving clinical outcomes.
Main Methods:
- Review of existing literature on cerebral edema pathophysiology and molecular mechanisms.
- Discussion of molecular targets in clinical trials, including ion channels (AQP4, SUR1-TRPM4) and signaling proteins (AVP, COX2, VEGF, S1P).
- Presentation of research on novel treatment modalities such as recombinant proteins and gene therapies.
Main Results:
- Inhibition of SUR1-TRPM4 (glyburide/glibenclamide) and VEGF (bevacizumab) are advanced in clinical trials.
- Bevacizumab has not shown a survival benefit in glioblastoma multiforme patients.
- Research into recombinant proteins and gene therapies for cerebral edema is in early stages but shows encouraging results.
Conclusions:
- Targeted molecular strategies represent a promising approach to manage cerebral edema.
- Further research into novel therapeutic modalities may enhance understanding of cerebral edema pathobiology.
- Emerging therapies hold potential for improved clinical outcomes in patients with brain injury.
More Related Videos
04:32Measuring Post-Stroke Cerebral Edema, Infarct Zone and Blood-Brain Barrier Breakdown in a Single Set of Rodent Brain Samples
Published on: October 23, 2020
06:24Paired Cisterna Magna Nanoinjection and Laser Speckle Contrast Imaging Assay to Study Cerebral Blood Flow Regulation In Vivo
Published on: July 8, 2025